Oppenheimer Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price

Y-mAbs Therapeutics (NASDAQ:YMAB - Free Report) had its price objective decreased by Oppenheimer from $20.00 to $15.00 in a research report sent to investors on Thursday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

YMAB has been the topic of a number of other reports. HC Wainwright dropped their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Wedbush reiterated an "outperform" rating and issued a $18.00 price target (down from $21.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, May 28th. Truist Financial reduced their price target on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Morgan Stanley dropped their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research report on Wednesday, March 5th. Finally, Bank of America downgraded shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 target price for the company. in a report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $15.60.

Y-mAbs Therapeutics Stock Performance

YMAB traded up $0.14 during trading on Thursday, hitting $4.74. 215,612 shares of the stock were exchanged, compared to its average volume of 308,215. The firm has a 50 day simple moving average of $4.37 and a 200 day simple moving average of $6.30. The firm has a market cap of $214.65 million, a price-to-earnings ratio of -8.78 and a beta of 0.53. Y-mAbs Therapeutics has a 1 year low of $3.55 and a 1 year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. The business had revenue of $20.90 million for the quarter, compared to the consensus estimate of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. As a group, equities analysts anticipate that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Thomas Gad sold 10,810 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. This trade represents a 5.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 22.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Large investors have recently bought and sold shares of the company. Brooklyn Investment Group lifted its stake in Y-mAbs Therapeutics by 4,563.8% during the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock valued at $26,000 after acquiring an additional 5,796 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Y-mAbs Therapeutics in the fourth quarter valued at $46,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Y-mAbs Therapeutics in the first quarter valued at $49,000. Corton Capital Inc. acquired a new stake in Y-mAbs Therapeutics during the 1st quarter worth about $55,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Y-mAbs Therapeutics during the 1st quarter valued at about $56,000. Hedge funds and other institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.